BUSINESS MATCHING, Coordination Between Inventors and the Directorate, The Use of Alera Gel in Cancer Patients Undergoing Radiation Therapy

The use of Alera Gel in cancer patients undergoing radiation therapy is part of a strategic effort to improve the quality of healthcare services focused on patient safety, comfort, and well-being. Radiation therapy, as one of the primary methods in cancer treatment, is highly effective in controlling the growth of cancer cells. However, this therapy also has the potential to cause side effects, particularly in skin tissue exposed to radiation, such as radiodermatitis, irritation, redness, and even open wounds, which can affect patient comfort and quality of life

In this context, Alera Gel is used as a supportive intervention designed to help mitigate the negative effects of radiation therapy. With ingredients formulated to soothe the skin, maintain moisture, and support tissue regeneration, Alera Gel helps accelerate skin recovery and prevent the worsening of radiation-induced skin lesions. Proper and measured use of this product can help patients undergo therapy more effectively, minimize physical discomfort, and reduce the risk of treatment discontinuation due to severe side effects.

The use of Alera Gel in cancer patients undergoing radiation therapy directly contributes to the achievement of SDG 3 (Good Health and Well-being) by improving the quality of healthcare services and managing the side effects of cancer treatment. With more comprehensive care support, patients have a greater chance of undergoing continuous and effective treatment.

In addition, this product innovation also supports SDG 9 (Industry, Innovation, and Infrastructure), particularly in terms of developing patient-centered healthcare technologies. The development and use of products such as Alera Gel reflect advancements in healthcare research and innovation, which aim to improve the quality of medical services and strengthen a healthcare system that is adaptable to clinical challenges.

Furthermore, Alera Gel also has the potential to contribute to SDG 12 (Responsible Consumption and Production), provided that its production and distribution processes, as well as the raw materials used, adhere to sustainability principles. This includes the use of safe and environmentally friendly materials, efficiency in production processes, and responsible waste management.

Specifically, contributions to SDG 3 can be broken down into several key targets, including:

Target 3.4: Reduce premature mortality from noncommunicable diseases, including cancer, through improved quality of medical care and comprehensive supportive care.

Target 3.8: Achieve universal access to quality, safe, effective, and affordable health care, including for the management of cancer treatment side effects.

By integrating primary therapy and supportive care, the use of Alera Gel focuses not only on clinical aspects but also on the patient’s overall quality of life. This initiative reflects a modern, holistic, innovative, and sustainable approach to healthcare, in line with the principles of the Sustainable Development Goals (SDGs).

Key SDG Supported: SDG 3 – Good Health and Well-being